Michael-Balint-Klinik, Königsfeld, Germany.
Expert Opin Drug Saf. 2010 May;9(3):397-406. doi: 10.1517/14740331003598857.
The question of whether different migraine and headache medications show a differential risk of medication overuse headache (MOH) induction has been discussed extensively but has not been definitively answered to date.
Clinical case series of interest that include statements on a differential risk of MOH development due to the use of different headache medications are identified by systematic literature research and analyzed.
In the present work, an expert evaluation is made of the existing evidence for different risks of different headache and migraine medications with regard to MOH occurrence, as has been claimed in various publications.
Despite several different attempts to obtain direct or indirect answers from clinical case series, the fact is that due to the intrinsic selection bias, confounding and other limitations inherent to clinical case series, they are not suitable to answer this question reliably. Thus, the repeated claims of a differential risk of different drugs and drug groups are simply not scientifically sound.
不同偏头痛和头痛药物是否会导致药物过度使用性头痛（MOH）的风险不同，这个问题已经被广泛讨论，但迄今为止尚未得到明确回答。
通过系统的文献研究确定了具有不同头痛药物使用导致 MOH 发展的差异风险的相关临床病例系列，并对其进行了分析。
在目前的工作中，对不同头痛和偏头痛药物发生 MOH 的不同风险的现有证据进行了专家评估，正如各种出版物中所声称的那样。
尽管有几种不同的尝试从临床病例系列中直接或间接获得答案，但事实是，由于内在的选择偏倚、混杂和其他固有的临床病例系列限制，它们不适合可靠地回答这个问题。因此，不同药物和药物组存在差异风险的反复说法在科学上是站不住脚的。
